Related Experiment Video
Updated: Aug 2, 2026
Viral Nanoparticles for In vivo Tumor Imaging
Published on: November 16, 2012
Mcl-1 small-molecule inhibitors encapsulated into nanoparticles exhibit increased killing efficacy towards
Christine M Burrer1, Helen Auburn1, Xu Wang2
1Department of Microbiology & Immunology, SUNY Upstate Medical University, Syracuse, NY 13210, United States.
Abstract:
Human cytomegalovirus (HCMV) spreads and establishes a persistent infection within a host by stimulating the survival of carrier myeloid cells via the upregulation of Mcl-1, an antiapoptotic member of the Bcl-2 family of proteins. However, the lack of potent Mcl-1-specific inhibitors and a targetable delivery system has limited the ability to exploit Mcl-1 as a therapeutic strategy to eliminate HCMV-infected monocytes. In this study, we found a lead compound from a novel class of Mcl-1 small-molecule inhibitors rapidly induced death of HCMV-infected monocytes. Moreover, encapsulation of Mcl-1 antagonists into myeloid cell-targeting nanoparticles was able to selectively increase the delivery of inhibitors into HCMV-activated monocytes, thereby amplifying their potency. Our study demonstrates the potential use of nanotechnology to target Mcl-1 small-molecule inhibitors to HCMV-infected monocytes.
Insights
Researchers developed novel Mcl-1 inhibitors and targeted nanoparticles to combat Human Cytomegalovirus (HCMV) by inducing death in infected monocytes, offering a new therapeutic strategy.
Area of Science:
- Virology
- Immunology
- Nanotechnology
- Drug Development
Background:
- Human Cytomegalovirus (HCMV) establishes persistent infections by promoting myeloid cell survival through Mcl-1 upregulation.
- Mcl-1, an antiapoptotic protein, is crucial for HCMV-infected monocyte survival.
- Current therapeutic strategies are limited by the lack of specific Mcl-1 inhibitors and targeted delivery systems.
Purpose of the Study:
- To identify and develop potent Mcl-1 inhibitors for therapeutic use against HCMV.
- To investigate the efficacy of myeloid cell-targeting nanoparticles for delivering Mcl-1 inhibitors.
- To explore the potential of targeting Mcl-1 in HCMV-infected monocytes.
Main Methods:
- Screening for novel small-molecule inhibitors targeting Mcl-1.
- Encapsulation of Mcl-1 antagonists into myeloid cell-targeting nanoparticles.
- Assessing the efficacy of inhibitors and nanoparticles in inducing death of HCMV-infected monocytes.
Main Results:
- A lead compound from a novel class of Mcl-1 inhibitors rapidly induced death in HCMV-infected monocytes.
- Nanoparticle encapsulation selectively enhanced inhibitor delivery into HCMV-activated monocytes.
- Targeted delivery amplified the potency of Mcl-1 inhibitors.
Conclusions:
- Novel Mcl-1 small-molecule inhibitors show promise for eliminating HCMV-infected monocytes.
- Myeloid cell-targeting nanoparticles can effectively deliver Mcl-1 inhibitors to infected cells.
- This nanotechnology-based approach offers a potential strategy to combat persistent HCMV infections.
